Fig 1: The levels of serum IL-37 in No-CAP and CAP cases. (A–F) The level of serum IL-37 was detected with ELISA. (A) The level of serum IL-37 in CAP patients and control subjects. (B) The level of serum IL-37 in different ranks of CRB-65 score of CAP. (C) The level of serum IL-37 in different ranks of SMART-COP score of CAP. (D) The level of serum IL-37 in different ranks of CURXO score of CAP. (E) The level of serum IL-37 in different ranks of SMART-COP score of CAP. (F) The level of serum IL-37 in different ranks of PSI score of CAP. *P < 0.05, **P < 0.01.
Fig 2: Receiver operating characteristic curves for different predictive biomarkers on admission. (A) ROC curve was used to evaluate the severity of different predictive biomarkers for CAP. (B) ROC curve was used to evaluate the death risk of different predictive biomarkers for CAP. (C) ROC curve was used to evaluate the death risk of serum IL-37 combination with CAP severity scores.
Fig 3: The levels of serum IL-37 in alive and dead CAP patients. (A, B) The level of serum IL-37 was detected with ELISA. (A) The level of serum IL-37 in alive and dead CAP patients. (B) The level of serum IL-37 in different hospital stay of CAP patients. *P < 0.05, **P < 0.01.
Supplier Page from CUSABIO Technology LLC for Human Interleukin 37(IL-37) ELISA Kit